Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

NIH Will Not Cap Funding to Individual Laboratories

The National Institutes of Health (NIH) is dropping its controversial proposal to limit grant funding to individual laboratories. The agency announced the plan in...

Pembrolizumab Trials Halt Enrollment After Patient Deaths

The FDA placed a clinical hold on three trials evaluating the PD-1 inhibitor pembrolizumab in patients with multiple myeloma (MM) following reports of patient...

All Clinical Trials of Vadastuximab Talirine Suspended Following Patient Deaths

Seattle Genetics, Inc., announced the discontinuation of the phase III CASCADE trial of vadastuximab talirine (also known as SGN-CD33A) in older patients with newly...

FDA Approves Rituximab and Hyaluronidase Combination for Several Lymphomas

The U.S. Food and Drug Administration has approved the subcutaneous injection formula of rituximab and hyaluronidase for the treatment of adults with follicular lymphoma...

FDA Approves Betrixaban for Venous Thromboembolism

The U.S. Food and Drug Administration (FDA) has approved betrixaban for the prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical...

FDA Panel Shows Support for Epoetin Biosimilar

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 14-1 to recommend approval of an epoetin alfa biosimilar agent. If approved by the FDA, this...

FDA Accepts New Drug Application for CPX-351 for AML

The FDA has accepted a new drug application (NDA) for CPX-351 – a liposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar...

Number of Physicians Who Own Their Own Practices Drops

The AMA’s biannual practice survey shows that the proportion of physicians who have an ownership stake in their own practices fell to 47.1 percent...

AMA Considers Backing the Disclosure of Drug Prices on Consumer Ads

Direct-to-consumer (DTC) advertising became legal in the United States in 1997 but has been debated ever since, with some groups claiming that this type...

NHLBI Announces New Funding Opportunities for Late-Stage Trials

The National Heart, Lung, and Blood Institute (NHLBI) announced two new funding opportunities for late-stage, single- or multi-site, investigator-initiated clinical trials that address critical...
Advertisement

Current Issue

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.